Evidence map›Paper›PMID 39281380›Full record

ArticleFrontiers in oncology2024

Radiosynthesis and

Yaxin Tian, Yanghongyan Jiang, Ping Ma, Xiaowei Ma, Liang Du, Fengkui Wang, Xiaodong Yu, Qian Zhao

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yaxin TianDepartment of Nuclear Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Yanghongyan JiangDepartment of Nuclear Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Ping MaDepartment of Nuclear Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Xiaowei MaDepartment of Nuclear Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Liang DuDepartment of Nuclear Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Fengkui WangDepartment of Nuclear Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Xiaodong YuDepartment of Nuclear Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Qian ZhaoDepartment of Nuclear Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Fibroblast activation protein (FAP) is highly expressed in the mesenchyme of most malignant epithelial tumors, while its expression is low in normal tissues. FAP inhibitors (FAPIs) bind specifically to FAP and are used for tumor-targeted diagnosis and therapy. The aim of this study was to radiosynthesize a novel molecular probe Methods: The structurally modified FAPI was labelled with Results: The radiolabeling rate was (84.9 ± 1.02) %. The radiochemical purity of Conclusion:

Indexed as

131Icancer-associated fibroblastsFAPIidentificationmolecular probe

Identifiers

PMID39281380
PMCPMC11392730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.